IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Fine Chemicals: Biologics Bounce Back

1:01 PM MST | January 18, 2008 | Deepti Ramesh with Alex Scott

It has been a long time coming, but contract manufacturers are finally beginning to reap financial rewards from their investment in large-molecule therapeutic drugs, also known as biologics or biopharmaceuticals. There have been casualties along the way, however, mainly due to the failure of drugs under development to reach the market. Casualties include Cambrex, which one year ago sold its biologics activities to Lonza, and DSM, which also in the past year was forced to shutter a large-scale biologics manufacturing plant at Montreal and subsequently sell the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa